Clinical Trials

Phase 3 Active not recruiting

Breast Neoplasms, Recurrence

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

373 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

198 enrolled

Breast Neoplasms

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Phase 1/2 Recruiting

196 enrolled

Breast Neoplasms

NCT06428396 2025-12-26

LITESPARK-029

Phase 2 Recruiting

120 enrolled

Breast Neoplasms

NCT03284957 2025-11-24

AMEERA-1

Phase 1/2 Terminated

136 enrolled 60 charts

Breast Neoplasms

NCT05501769 2025-09-26

TACTIVE-E

32 enrolled

Breast Neoplasms

NCT06680921 2025-09-22

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

Phase 3 Recruiting

460 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT04188548 2025-06-04

EMBER

500 enrolled

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT05293964 2024-11-29

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

Phase 1 Active not recruiting

214 enrolled

Breast Neoplasms

NCT05065411 2024-02-26

VERU-024

Phase 3 Terminated

5 enrolled

Breast Neoplasms

NCT03312738 2024-01-23

BOLERO-5

159 enrolled 25 charts

Breast Neoplasms

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

283 enrolled 22 charts

Breast Neoplasms

NCT01698918 2023-05-03

BOLERO-4

202 enrolled 19 charts

Breast Neoplasms

NCT05108740 2021-12-09

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

No longer available

Breast Neoplasms

NCT01857193 2021-04-13

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

132 enrolled

Breast Neoplasms

NCT01231659 2021-03-26

Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

72 enrolled 11 charts

Breast Neoplasms

NCT01783444 2021-02-26

BOLERO-6

309 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00426530 2020-12-21

Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

50 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT01482156 2020-12-21

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

46 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell

NCT02077933 2020-12-08

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

79 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

NCT03176238 2020-04-07

EVEREXES

235 enrolled 11 charts

Breast Neoplasms

NCT01743560 2019-07-18

4EVERUK

Phase 4 Completed

52 enrolled 16 charts

Breast Diseases, Breast Neoplasms, Neoplasms, Skin Diseases

NCT00876395 2018-12-19

BOLERO-1

719 enrolled 25 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02248571 2017-11-13

IMPROVE

Phase 4 Completed

85 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT00863655 2017-05-02

BOLERO-2

724 enrolled 20 charts

Breast Neoplasms

NCT01007942 2017-04-05

BOLERO-3

569 enrolled 16 charts

Breast Neoplasms

NCT01626222 2017-02-23

MACS2096

301 enrolled

Breast Neoplasms

NCT02023359 2015-12-29

Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

Completed

7 enrolled

Breast Neoplasms

NCT00426556 2015-12-28

Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

88 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00107016 2013-03-04

Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women

267 enrolled